Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | RELEVANCE study: the R-squared regimen for follicular lymphoma

The RELEVANCE study (NCT01476787) looks at the ‘R-squared’ regimen that combines lenalidomide and rituximab for the treatment of follicular lymphoma. Here, Wojciech Jurczak, MD, PhD, from Jagiellonian University, Kraków, Poland, describes the outcomes of the trial, and makes a case for obinutuzumab in place of rituximab, in hope of demonstrating superiority over current first-line therapies. Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Prof. Jurczak discusses other upcoming combinations with immunotherapeutic agents, particularly lenolidamide and CC-122, which increases the potency of T-cell signaling. Prof. Jurczak also touches upon the current and future use of chemotherapies, which, while tending to have poor side effect profiles, remain effective in treating various hematological malignancies.